

DRUG PRIOR AUTHORIZATION COMMITTEE MEETING
December 16, 2021
MO HealthNet
VIA WEBEX ONLY

Committee Members Present:

Angeline Stanislaus, MD
J.K. Sturgeon, PharmD, BCPS
Laura Kingsley, PharmD
Matthew Stinson, MD
Maya Moody, DO, FAAP
Morgan Sperry, PharmD

Committee Members Absent:

Conrad Balcer, DO, Chair

MO HealthNet Staff Present:

Joshua Moore, PharmD, Director of
Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Angela Wilson, Pharmacy Operations
Manager
Olivia Rush, PharmD, Program Integrity
Pharmacist
Elizabeth Sissom, RN, Clinical
Management
Lisa E. Smith, Program Development
Specialist
Carmen Burton, Administrative Assistant
Timothy Kling, MD, Acting Medical
Director
Elizabeth Short, Program Development
Specialist
Connie Sutter, Fiscal Manager
Kathy Heriford, Benefit Program Senior
Specialist

Contractors in Attendance:

April Ash, PharmD, Conduent
Blake Shrout, PharmD, AAHIVP,
Conduent
Jennifer Colozza, PharmD, Conduent
Luke Boehmer, PharmD, Conduent
Megan Fast, PharmD, Conduent
Paul Fung, PharmD, Conduent
Sandra Kapur, PharmD, Conduent
Serena Barden, PharmD, BCPS,
Conduent
Chelsea Pendleton, RN, BSN, Wipro
Geri Roling, RN, Wipro
Valerie Schmitz, RN, BSN Wipro
Ashley Lytton, RN, Wipro

Others Attending:

Adam Kopp
Ahmed Taranissi
Akesha Coleman
Angelo Manifest
Ashok V
Audrey Rattan
Ava Bamdad
Bashir Kalayeh
Bobbi Bentz
Brad Willie
Brent
Brian Strickland

Brooke Wilkins
Bryan
Camille Kerr
Chris VandeVen
Chris Voyiatt
Christy Galeotti
Dan McCall
Dave Miley
Dave Poskey
David Large
Doug Wood
Emily Smith
Erin Hohman
Frank Alvarado
Garth Wright
Gregory Mattingly
Heather Higgins
Jamie Tobitt
Jenny Carrell
Jessica Crews
Jessica Petrie
JJ Roth
K Gulley
Kamile Johnson
Karen Evenson
Karen Floeder
Karen Malamut
Kenneth Berry
Kevin Hinthorne

Kurt Hendrickson
Lance Salazar
Lindsey Bebout
Marilyn
Mark Kaiser
Matt Stroh
Melissa Basil
Michael Holmes
Michele Shirley
Paul Amato
Phillip King
Porscha Showers
Raquel Jordan
Ricki Roberson
Rob Hansen
Rob Kilo
Robert Pearce
Sean Jones
Shauna Williams
Stacy Sandate
Stephanie
Stevens
Stormy Cameron
Susie Moroney
Tami Sova
Tammy Martin
Terry
Tina Rhinehart
Tom Guyer
Tom Seignious
Tracy Pellegrino

DRAFT

<p>Welcome, Introductions and Opening Remarks</p>	<p>Morgan Sperry, Board Member, called the meeting to order.</p> <p>Joshua Moore, MHD Director of Pharmacy, introduced himself along with new DPAC committee member Maya Moody. Joshua facilitated the meeting on behalf of the MO HealthNet Division.</p>
<p>Minutes Review</p>	<p>Discussion: Minutes were reviewed from the September 2021 meeting.</p> <p>Decision: The committee voted to accept these approved minutes with no revisions.</p>
<p>Pharmacy Program and Budget Update</p>	<p>Elizabeth Short and Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - July-Oct 2021 Eligibles by Group - July-Oct 2021 Expenditures by Enrollment Group - July-Oct 2021 Expenditures by Service - FY22 Pharmacy Spend vs July-Oct 2021 Total Medicaid Spend - FY22 Pharmacy Expenditures - Top 4 Drug Classes per FY22 - Pharmacy Expenditures/Eligibles per FY (2015 – 2021) - Hep C Spend and Utilization FY18 – FYTD22 - Synagis Expenditures FY19 – FYTD22 - FY19 – FYTD22 Rare Disease Expenditures - Continuous Glucose Monitor policy updates - Streamlining older edits to help decrease call volume to the helpdesk and overall enhanced workflow for all those involved - Reminder that MHD now accepts and edits a diagnosis code submitted on the point of sale claims - Enhancing education efforts with hot tips and blasts - Pharmacy Signature Log Requirements – hot tip went out 12/15/21 - Prenatal vitamins coverage updates - COVID home test coverage

Old Business	
Old Business	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm</p>
New Business	
New Drug Review	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> o A listing of products recommended for open access, clinical edit, preferred drug list (PDL), or continue prior authorization was emailed to the Board for discussion and action. - No other discussion. - No public comment provided. <p>Decision: The committee voted to accept the presented new drug recommendations with no revisions.</p>

Opioid Policy Review

High Risk Therapies Clinical Edit

Discussion:

- Joshua Moore introduced the edits for discussion to the Board which included:
- Discussion arose on adding opioid + sedative hypnotics and opioid + gabapentin to the edit; after discussion the following criteria change was proposed:
 - o Claim is for an opioid (excluding buprenorphine tablets and buprenorphine/naloxone combinations) and:
 - Participant has history of > 3 days of **oral benzodiazepine therapy** in the past 60 days **OR**
 - **Participant has history of > 3 days of select sedative hypnotic therapy (eszopiclone, zaleplon, or zolpidem) in the past 60 days OR**
 - **Participant has history of > 3 days of gabapentinoid therapy (gabapentin or pregabalin) in the past 60 days AND**
 - Participant lacks history of at least 1 claim for an opioid emergency reversal agent in the past 2 years
 - o Claim is for **an oral benzodiazepine, a select sedative hypnotic (eszopiclone, zaleplon, or zolpidem), or a gabapentinoid (gabapentin or pregabalin)** and:
 - Participant has history of > 7 days of opioid therapy (excluding buprenorphine tablets and buprenorphine/naloxone combinations) in the past 60 days **AND**
 - Participant lacks history of at least 1 claim for an opioid emergency reversal agent in the past 2 years
- Reminder that it is important for pharmacists and providers to educate patients on the safety aspects of the naloxone, not only for them but others who could access their prescriptions.
- No public comment provided.

Decision: The Board voted to accept the recommended criteria with the additional revisions above in blue.

<p>Morphine Milligram Equivalent (MME) Accumulation Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>- Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Opioid Dependence Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment was provided by: <ul style="list-style-type: none"> o Kenneth Berry with Alkermes on Vivitrol yielded time back o Lindsay Bebout with Indivior on Sublocade yielded time back <p>- Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Opioid Emergency Reversal Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>- Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Opioids, Long Acting PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>- Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Opioids, Short Acting Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>- Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Tramadol-Like Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>- Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>- Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

Clinical and Fiscal Edit Review	
<p align="center">Clinical & Fiscal Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o 15 Day Supply Oral Oncology Fiscal Edit o Butalbital Combinations without Codeine Clinical Edit o Butalbital Combinations Excessive Therapy Edit o Diabetic Supply Quantity Limit Fiscal Edit o Out-of-State, Non-Bordering Pharmacies Fiscal Edit o Selzentry Clinical Edit - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">15 Day Supply Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Acetaminophen Cumulative Dose Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Antipsychotics, 1st Generation (Typical) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Antipsychotics, 2nd Generation (Atypical) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Clarification was provided on the difference between a reference and non-reference list. - Public comment was provided by: <ul style="list-style-type: none"> o Erin Hohman with Abbvie on Vraylar yielded time back o Kenneth Berry with Alkermes on Aristada, Aristada Initio and Lybalvi yielded time back o Lindsay Bebout with Indivior on Perseris yielded time back <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Benzodiazepine, Select Oral Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Discussion arose around the wording regarding the benzodiazepine naïve participants being confusing for providers. MHD to work on phrasing of the proposal to help bring clarity to the criteria. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>BiDil Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Biosimilar vs. Reference Products Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Corlanor Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Empaveli Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Jamie Tobitt with Apellis on Empaveli <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Extended Supply Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Discussion arose on adding a liquid formulation of melatonin to help decrease the use of other sleep aids. MHD to take suggestion back to group to evaluate. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>High Cost Medications Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Clarification was provided that a letter of medical necessity would need to be submitted for review if a high cost medication was requested. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Kerendia Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Bashir Kalayeh with Bayer on Kerendia yielded time back <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Non-Oral Contraceptives Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Discussion arose regarding MHD maintenance medication dispensing fee limitation and how the affected the agents within this class. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Pompe Disease Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Spinal Muscular Atrophy (SMA) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Tami Sova with Biogen on Spinraza yielded time back <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

Preferred Drug List Edit Review	
<p>Preferred Drug Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Alzheimer’s Agents, AChEIs and NMDA Receptor Antagonists o Anticonvulsants, Dravet Syndrome o Antiemetics, THC Derivatives o Anti-Parkinsonism, MAO-B Inhibitors o Anti-Parkinsonism, Non-Ergot Dopamine Agonists o GI Motility Agents, Chronic o Sedative Hypnotics o Somatostatin Analogs - Public comment provided by: <ul style="list-style-type: none"> o Matt Stroh with Zogenix on Fintepla o Susie Moroney with Novartis on Sanostatin LAR yielded time back - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Antiandrogenic Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Antiemetics, 5-HT3 and NK1 Injectables</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Anti-Migraine, Alternative Oral Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Erin Hohman with Abbvie on Ubrelvy o Tammy Martin with BioHaven on Nurtec ODT yielded time back <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Anti-Migraine, Serotonin (5-HT1) Receptor Agonists</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Antiretroviral Therapy (ART)</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Clarification was provided regarding the approval criteria for a preferred agent in Group B: <ul style="list-style-type: none"> o Claim is for an agent in Group B <ul style="list-style-type: none"> ▪ For preferred agents: failure to achieve desired therapeutic outcomes with trial on 1 Group A agent - Public comment provided by: <ul style="list-style-type: none"> o Karen Malamut and Boris Renjifo with Merck & Co on Pifeltro and Delstrigo yielded time back o Lance Salazar with Janssen on Symtuza o Paul Amato with ViiV Healthcare on Cabenuva and Dovato o Porscha Showers with Gilead on Biktarvy yielded time back o Kamile Johnson with KC Care <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Bile Salt Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Stacy Sandate with Albireo on Bylvay <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Calcitonin Gene-Related Peptide (CGRP) Inhibitors</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Bobbi Bentz with Lilly on Emgality o Dave Miley with Teva on Ajovy yielded time back <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Susie Moroney with Novartis on Kisqali <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Fibromyalgia Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p style="text-align: center;">Glucagon Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Emily Smith with Zealand on Zegalogue o Angelo Manifest with Xeris Pharmaceuticals on Gvoke <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p style="text-align: center;">Hereditary Angioedema Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p style="text-align: center;">Homozygous Familial Hypercholesterolemia (HoFH)</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Tracy Pellegrino with Regeneron on Evkeeza yielded time back <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p style="text-align: center;">Neuropathic Pain Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose around the PA process for gabapentin solution for a participant 10 and younger. It was explained these claims would not require a PA or call to the help desk. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p style="text-align: center;">NSAIDs</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Skeletal Muscle Relaxants</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Dave Miley with Teva on Austedo yielded time back o John Deason III with Neurocrine Biosciences on Ingrezza o Gregory Mattingly with Washington University on Ingrezza o Ahmed Taranissi on Ingrezza <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Preferred Drug List Announcement</p>	<p>A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and March 2022 meeting was included in the meeting packet.</p> <p>This handout was also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm</p>
<p>Program Utilization Information – Conduent Update</p>	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Top 25 Drugs by Paid Amount 1st Quarter 202 (July, August, September) - Top 25 Drugs by Paid Number 1st Quarter 202 (July, August, September) - Call Center User Statistics November 2021 - CyberAccess Logging Information - New Drug Statistics November 2021
<p>Adjournment</p>	<p>Laura Kingsley motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. The next meeting of the Drug Prior Authorization Committee is scheduled via hybrid meeting (in person and WebEx) on Thursday, March 17, 2022.</p>

Roll Call for December 16, 2021

	<u>Committee Member</u>						
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson	J.K. Sturgeon	Maya Moody
September 2021 Minutes	A	MY	Y	SY	Y	Y	Y
New Drug Review	A	Y	Y	SY	MY	Y	Y
High Risk Therapies Clinical Edit	A	MY	Y	SY	Y	Y	Y
Morphine Milligram Equivalent (MME) Accumulation Clinical Edit	A	Y	Y	SY	MY	Y	Y
Opioid Dependence Agents PDL Edit	A	Y	Y	SY	MY	Y	Y
Opioid Emergency Reversal Agents PDL Edit	A	Y	Y	SY	MY	Y	Y
Opioids, Long Acting PDL Edit	A	MY	Y	SY	Y	Y	Y
Opioids, Short Acting Clinical Edit	A	SY	Y	Y	MY	Y	Y
Tramadol-Like Agents PDL Edit	A	MY	Y	Y	Y	SY	Y
Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit	A	Y	Y	SY	MY	Y	Y
Clinical/Fiscal Edit – No Changes	A	Y	Y	SY	MY	Y	Y
15 Day Supply Fiscal Edit	A	MY	Y	SY	Y	Y	Y
Acetaminophen Cumulative Dose Clinical Edit	A	Y	Y	MY	Y	SY	Y

Roll Call for December 16, 2021

	<u>Committee Member</u>						
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson	J.K. Sturgeon	Maya Moody
Antipsychotics, 1st Generation (Typical) Clinical Edit	A	MY	Y	SY	Y	Y	Y
Antipsychotics, 2nd Generation (Atypical) Clinical Edit	A	SY	Y	MY	N	Y	Y
Benzodiazepine, Select Oral Clinical Edit	A	MY	Y	SY	Y	Y	Y
BiDil Clinical Edit	A	SY	Y	MY	Y	Y	Y
Biosimilar vs. Reference Products Fiscal Edit	A	MY	Y	Y	Y	SY	Y
Contraceptives Fiscal Edit	A	MY	Y	Y	Y	Y	SY
Corlanor Clinical Edit	A	MY	Y	SY	Y	Y	Y
Empaveli Clinical Edit	A	MY	Y	SY	Y	Y	Y
Extended Supply Fiscal Edit	A	SY	Y	Y	MY	Y	Y
High Cost Medications Fiscal Edit	A	Y	Y	SY	MY	Y	Y
Kerendia Clinical Edit	A	SY	Y	Y	MY	Y	Y
Pompe Disease Clinical Edit	A	Y	Y	SY	Y	Y	MY

Roll Call for December 16, 2021

	<u>Committee Member</u>						
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson	J.K. Sturgeon	Maya Moody
Spinal Muscular Atrophy (SMA) Clinical Edit	A	SY	Y	Y	Y	Y	MY
Preferred Drug List Edits With No Annual Changes	A	Y	Y	MY	Y	SY	Y
Antiandrogenic Agents	A	MY	Y	SY	A	Y	Y
Antiemetics, 5-HT3 and NK1 Injectables	A	Y	Y	MY	Y	SY	Y
Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables	A	SY	Y	MY	Y	Y	Y
Anti-Migraine, Alternative Oral Agents	A	Y	Y	MY	Y	SY	Y
Anti-Migraine, Serotonin (5-HT1) Receptor Agonists	A	MY	Y	SY	Y	Y	Y
Antiretroviral Therapy (ART)	A	MY	Y	Y	Y	SY	Y
Bile Salt Agents	A	Y	Y	MY	Y	SY	Y
Calcitonin Gene-Related Peptide (CGRP) Inhibitors	A	Y	Y	MY	SY	Y	Y

Roll Call for December 16, 2021

	<u>Committee Member</u>						
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson	J.K. Sturgeon	Maya Moody
Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors	A	MY	Y	Y	Y	SY	Y
Fibromyalgia Agents	A	Y	Y	SY	Y	MY	Y
Glucagon Agents	A	Y	Y	MY	Y	SY	Y
Hereditary Angioedema Agents	A	MY	Y	SY	A	Y	Y
Homozygous Familial Hypercholesterolemia (HoFH)	A	MY	Y	Y	A	SY	Y
Neuropathic Pain Agents	A	MY	Y	SY	Y	Y	Y
NSAIDs	A	MY	Y	Y	Y	SY	Y
Skeletal Muscle Relaxants	A	SY	Y	Y	Y	MY	Y
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors	A	Y	Y	Y	MY	SY	Y
Motion to Close	A	MY	Y	SY	Y	A	Y
Adjournment	A	MY	Y	SY	Y	A	Y

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain